Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results

- Revenue up 18% to $9.8 million

NASHVILLE, Tenn., Aug. 27 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals
Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the
hospital acute care and gastroenterology markets, today announced second
quarter 2009 financial results.

"Our second quarter and the weeks since have encompassed two of the most
significant events in the Company's history--receipt of Food and Drug
Administration (FDA) approval for Caldolor and the completion of our initial
public offering," said A.J. Kazimi, Chief Executive Officer at Cumberland.
"We have also completed the expansion of our hospital sales force to
facilitate a successful product launch of Caldolor, our injectable ibuprofen
product. We believe Caldolor will offer an important alternative for
physicians in treating patients with fever or pain where oral treatment is not
ideal or even a viable option."

Net Revenue: For the three months ended June 30, 2009, net revenue was $9.8
million, up 18% from the corresponding period in 2008. This growth was
primarily attributable to an increase in volume for Acetadote, the Company's
injectable treatment for acetaminophen overdose. Net revenue for the six
months ended June 30, 2009, was $19.2 million, compared with $16.7 million for
the same period in 2008.

Operating Expenses: Total operating expenses for the three months ended June
30, 2009, were $9.2 million, compared to $6.5 million for the same period in
2008. The increase in expenses was due primarily to milestone payments
associated with FDA approval of Caldolor, as well as increased marketing
expenses for that product. For the six-month period ended June 30, 2009,
total operating expenses were approximately $16.5 million, compared with $13.0
million for the corresponding period in 2008. This increase was primarily a
result of the Caldolor milestone obligations, costs incurred in connection
with the expansion of the hospital sales force and increased marketing and
advertising costs.

Net Income: Net income for the three months ended June 30, 2009, was $0.3
million, or $0.02 per diluted share, compared to $1.1 million, or $0.07 per
diluted share, for the same period in 2008. Net income for the six months
ended June 30, 2009, was $1.5 million, or $0.09 per diluted share, compared to
$2.5 million, or $0.15 per diluted share, for the corresponding period in
2008. The decrease in both periods was due primarily to milestone obligations
triggered by FDA approval of Caldolor in the second quarter of 2009, as well
as the aforementioned sales force expansion.

Cash and Cash Equivalents: At June 30, 2009, Cumberland had $12.5 million in
cash and cash equivalents, compared to $10.1 million at March 31, 2009,
representing an increase of $2.4 million. At June 30, 2009, the Company had
net accounts receivable and inventories of approximately $3.3 million and $1.1
million, respectively. Included in current assets is an income tax receivable
of approximately $1.8 million that was a result of a tax benefit associated
with the exercise of stock options during the first quarter of 2009. Total
working capital was approximately $12.0 million and the current ratio was
2.5x.

Recent Events

Caldolor Approval and Launch Preparation: In June 2009, Cumberland received
FDA approval for Caldolor, the first injectable product approved in the United
States for the treatment of pain and fever. Cumberland recently completed an
expansion that nearly tripled the size of its hospital sales force in
preparation for the product's launch, increasing the size of this group from
27 to 77 experienced hospital representatives and managers.

"We expect Caldolor to be used to treat pain either as a stand-alone agent or
as a multi-modal treatment in conjunction with opioids. Caldolor is also
approved to treat fever in the acute care setting, where existing alternatives
to oral treatment often include the use of cold blankets and ice packs," says
Kazimi. "We believe Caldolor has an excellent safety profile, supported by a
long history of ibuprofen use as well as our clinical trial database that
shows no serious adverse events associated with the product and no significant
safety difference compared to placebo."

Initial Public Offering: In early August 2009, Cumberland completed an
initial public offering of 5,000,000 shares of common stock, raising $85.0
million in gross proceeds. Net proceeds to the Company are estimated to be
approximately $75.2 million after deducting underwriting discounts and
commissions as well as offering expenses, and before exercise of any
over-allotment option. Cumberland expects to use these proceeds primarily for
the pending launch of Caldolor and for potential acquisitions.

Conference Call and Webcast

A conference call and live webcast will be held on Thursday, August 27, 2009,
at 10:00 a.m. Eastern Time to discuss the Company's second quarter 2009
financial results. To participate on the call, please dial 877-604-9672 (for
U.S. callers) or 719-325-4909 (for international callers). A rebroadcast of
the teleconference will be available for one week and can be accessed by
dialing 888-203-1112 (for U.S. callers) or 719-457-0820 (for international
callers). The passcode for the rebroadcast is 7834064. The live webcast and
rebroadcast can be accessed via Cumberland Pharmaceuticals' website at
http://investor.shareholder.com/cpix/events.cfm.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical
company focused on the acquisition, development and commercialization of
branded prescription products. The Company's primary target markets include
hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for
the treatment of acetaminophen poisoning and Kristalose(R), a prescription
laxative. The Company also recently received FDA approval for Caldolor(R), the
first injectable treatment for pain and fever available in the United States,
and is preparing for the commercial launch of that product. Cumberland is
dedicated to providing innovative products which improve quality of care for
patients.

For more information on Cumberland Pharmaceuticals, please visit
www.cumberlandpharma.com.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and
management of moderate to severe pain as an adjunct to opioid analgesics, as
well as the reduction of fever in adults. It is the first FDA approved
intravenous therapy for fever. Caldolor is contraindicated in patients with
known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma,
urticaria, or allergic type reactions after taking aspirin or other NSAIDs.
Caldolor is contraindicated for use during the peri-operative period in the
setting of coronary artery bypass graft (CABG) surgery. Caldolor should be
used with caution in patients with prior history of ulcer disease or GI
bleeding, in patients with fluid retention or heart failure, in the elderly,
those with renal impairment, heart failure, liver impairment, and those taking
diuretics or ACE inhibitors. Blood pressure should be monitored during
treatment with Caldolor. For full prescribing information, visit
www.caldolor.com.

About Acetadote

Acetadote is used in the emergency department to prevent or lessen potential
liver damage resulting from an overdose of acetaminophen, a common ingredient
in many over-the-counter painkillers. It is the only approved injectable
product in the United States for the treatment of acetaminophen overdose, the
leading cause of poisonings presenting in emergency departments in the
country(1). Acetadote is contraindicated in patients with hypersensitivity or
previous anaphylactoid reactions to acetylcysteine or any components of the
preparation. Serious anaphylactoid reactions, including death in a patient
with asthma, have been reported in patients administered acetylcysteine
intravenously. Acetadote should be used with caution in patients with asthma,
or where there is a history of bronchospasm. The total volume administered
should be adjusted for patients less than 40 kg and for those requiring fluid
restriction. To avoid fluid overload, the volume of diluent should be reduced
as needed. If volume is not adjusted, fluid overload can occur, potentially
resulting in hyponatremia, seizure, and death. For full prescribing
information, visit www.acetadote.net.

About Kristalose

Kristalose is indicated for the treatment of acute and chronic constipation.
It is a unique, proprietary, crystalline form of lactulose, with no
restrictions on length of therapy or patient age. Initial dosing may produce
flatulence and intestinal cramps, which are usually transient. Excessive
dosage can lead to diarrhea with potential complications such as loss of
fluids, hypokalemia and hypernatremia. Nausea and vomiting have been
reported. Use with caution in diabetics. Kristalose is contraindicated in
patients who require a low-galactose diet. Elderly, debilitated patients who
receive lactulose for more than six months should have serum electrolytes
(potassium, chloride, carbon dioxide) measured periodically. For full
prescribing information, visit www.kristalose.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act and Section 21E of the Exchange Act, including statements
regarding estimated results of operations in future periods. These
forward-looking statements are subject to the finalization of Cumberland's
quarterly financial and accounting procedures and reflect Cumberland's current
views with respect to future events, based on what it believes are reasonable
assumptions. No assurance can be given, however, that these events will occur.
As with any business, all phases of Cumberland's operations are subject to
influences outside its control. Any one, or a combination, of these factors
could materially affect the results of the Cumberland's operations. These
factors include among other things, market conditions, the commercialization
of Caldolor, Cumberland's dependence on Acetadote and Kristalose to generate
almost all of its revenues, intense competition from existing and new
products, which could diminish the commercial potential of Cumberland's
products, an inability of manufacturers to produce Cumberland's products on a
timely basis or a failure of manufacturers to comply with stringent
regulations applicable to pharmaceutical drug manufacturers, maintaining and
building an effective sales and marketing infrastructure, Cumberland's ability
to identify and acquire rights to products, government regulation, the
possibility that Cumberland's marketing exclusivity and patent rights may
provide only limited protection from competition, and other factors discussed
in our Registration Statement declared effective by the SEC on August 10,
2009. There can be no assurance that the results or developments anticipated
by the Company will be realized or, even if substantially realized, that they
will have the expected consequences to or effects on the Company or its
business and operations. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. The
Company does not undertake any obligation to release publicly any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events.

(1) National Poison Data System, American Association of Poison Control
Centers

CUMBERLAND PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

December 31, June 30,
2008 2009
---- ----
ASSETS

Current assets:
Cash and cash equivalents $11,829,551 $12,531,110
Accounts receivable, net of
allowances 3,129,347 3,254,371
Inventories 1,762,776 1,108,376
Prepaid and other current
assets 481,312 709,511
Income taxes receivable - 1,800,632
Deferred tax assets 507,212 507,212
------- -------

Total current assets 17,710,198 19,911,212

Property and equipment, net 432,413 505,174
Intangible assets, net 8,528,732 8,226,047
Deferred tax assets 1,000,031 1,000,031
Other assets 3,447,813 3,705,275
--------- ---------

Total assets $31,119,187 $33,347,739

LIABILITIES AND EQUITY

Current liabilities:
Current portion of long-term
debt $1,250,000 $1,666,667
Current portion of other
long-term obligations 457,915 1,263,491
Accounts payable 3,257,164 2,420,175
Other accrued liabilities 2,640,855 2,586,396
--------- ---------

Total current liabilities 7,605,934 7,936,729

Revolving line of credit 1,825,951 1,825,951
Long-term debt, excluding
current portion 3,750,000 2,916,666
Other long-term obligations,
excluding current portion 382,487 159,165
------- -------

Total liabilities 13,564,372 12,838,511
---------- ----------

Commitments and contingencies

Redeemable common stock - 630,000

Shareholders' equity:
Cumberland Pharmaceuticals Inc.
shareholders' equity:
Convertible preferred stock -
no par value; 3,000,000 shares
authorized; 812,749 shares
issued and outstanding 2,604,070 2,604,070
Common stock - no par value;
100,000,000 shares authorized;
9,903,047 and 10,475,693(1) shares
issued and outstanding
as of December 31, 2008 and
June 30, 2009, respectively 13,500,034 14,331,181
Retained earnings 1,450,711 2,964,672
--------- ---------
Total shareholders' equity 17,554,815 19,899,923
---------- ----------

Noncontrolling interests - (20,695)
--- -------
Total equity 17,554,815 19,879,228
---------- ----------

Total liabilities and equity $31,119,187 $33,347,739

(1) Number of shares issued and outstanding represents total shares
of common stock regardless of classification on the consolidated
balance sheet. The number of shares of redeemable common stock at
June 30, 2009 was 42,000.

CUMBERLAND PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)

Three months ended Six months ended
June 30, June 30,
-------------------- ---------------------
2008 2009 2008 2009
---- ---- ---- ----

Net revenues $8,357,532 $9,820,613 $16,661,359 $19,225,212

Costs and expenses:
Cost of products
sold 737,230 777,076 1,492,721 1,510,294
Selling and
marketing 3,644,796 4,383,802 7,008,802 8,523,989
Research and
development 918,460 2,630,725 2,028,402 3,400,842
General and
administrative 1,021,639 1,236,435 2,104,733 2,681,298
Amortization of
product license
right 171,726 171,726 343,452 343,452
Other 25,193 26,733 51,222 54,196
------ ------ ------ ------
Total costs and
expenses 6,519,044 9,226,497 13,029,332 16,514,071
--------- --------- ---------- ----------

Operating income 1,838,488 594,116 3,632,027 2,711,141

Interest income 50,647 10,160 133,019 27,756
Interest expense (10,377) (84,224) (123,981) (181,935)
------- ------- -------- ---------

Net income before
income taxes 1,878,758 520,052 3,641,065 2,556,962

Income tax
expense (820,335) (232,637) (1,187,392) (1,063,696)
-------- -------- ----------- ----------

Net income 1,058,423 287,415 2,453,673 1,493,266

Net loss at
subsidiary
attributable to
noncontrolling
interests - 8,456 - 20,695
--- ----- --- ------

Net income
attributable to
common
shareholders $1,058,423 $295,871 $2,453,673 $1,513,961
========== ======== ========== ==========

Earnings per
share
attributable to
common
shareholders -
basic $0.10 $0.03 $0.24 $0.15
Earnings per
share
attributable to
common
shareholders -
diluted $0.07 $0.02 $0.15 $0.09

CUMBERLAND PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

Six Months Ended June 30,
-------------------------
2008 2009
---- ----

Cash flows from operating activities:
Net income $2,453,673 $1,493,266
Adjustments to reconcile net income to net
cash flows from operating activities:
Gain on early extinguishment of other
long-term obligations (38,577) -
Depreciation and amortization expense 392,896 398,341
Nonemployee stock granted for services
received 27,500 182,091
Nonemployee stock option grant expense - 826,290
Stock-based compensation - employee stock
options 121,725 313,064
Excess tax benefit derived from exercise of
stock options (156,758) (2,842,825)
Noncash interest expense 63,113 29,376
Net changes in assets and liabilities
affecting operating activities:
Accounts receivable (627,785) (125,024)
Inventory 1,110 654,400
Prepaid, other current assets and other
assets 625,462 743,951
Accounts payable and other accrued
liabilities (8,332) (986,592)
Other long-term obligations 47,856 582,254
------ -------
Net cash provided by operating activities 2,901,883 1,268,592
--------- ---------

Cash flows from investing activities:
Additions to property and equipment (54,259) (85,863)
Additions to patents (41,791) (34,551)
------- -------
Net cash used in investment activities (96,050) (120,414)
------- --------

Cash flows from financing activities:
Costs of initial public offering (322,664) (154,179)
Principal payments on note payable (916,668) (416,667)
Net borrowings on line of credit 500,000 -
Payment of other long-term obligations (2,760,000) -
Costs of financing for long-term debt and
credit facility - (15,475)
Proceeds from exercise of stock options 39,098 4,296
Excess tax benefit derived from exercise of
stock options 156,758 2,842,825
Payments made in connection with repurchase
of common shares - (2,707,419)
--- -----------
Net cash used in financing activities (3,303,476) (446,619)
----------- --------

Net (decrease) increase in cash and cash
equivalents (497,643) 701,559

Cash and cash equivalents at beginning of
period 10,814,518 11,829,551
---------- ----------

Cash and cash equivalents at end of period $10,316,875 $12,531,110
=========== ===========

SOURCE Cumberland Pharmaceuticals Inc.

Angela Novak, Corporate Relations of Cumberland Pharmaceuticals Inc.,
+1-615-255-0068, anovak@cumberlandpharma.com; or Kathy Waller of Financial
Relations Board, +1-312-543-6708, for Cumberland Pharmaceuticals Inc.